BRAF V600E mutations are found in multiple tumor types, and BRAF inhibitors in combination with MEK inhibitors are part of the standard of care (SOC) in BRAF-mutant melanoma and non-small cell lung cancer3,4. The gene discussed is BRAF; the disease is neoplasm.